Case study for a vaccine against leishmaniasis

Vaccine

Volumn 31, Issue SUPPL2, 2013, Pages

  Alvar, Jorge ^a   Croft, Simon L ^b   Kaye, Paul ^c   Khamesipour, Ali ^d   Sundar, Shyam ^e   Reed, Steven G ^f  

^a Chemin Louis Dunant ^*  (Switzerland)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^c UNIVERSITY OF YORK   (United Kingdom)

^d TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^e BANARAS HINDU UNIVERSITY   (India)

^f INFECTIOUS DISEASE RESEARCH INSTITUTE   (United States)

Author keywords

Adjuvant; Leishmaniasis; Vaccine

Indexed keywords

BCG VACCINE; CYSTEINE PROTEASE GENE B; GAMMA INTERFERON; HYDROPHILIC ACYLATED SURFACE PROTEIN B FAMILY; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 12; KINETOPLASTID MEMBRANE PROTEIN 11; LCR1 PROTEIN; LEISHMANIA ELONGATION INITIATION FACTOR; LEISHMANIA HOMOLOGUE OF RECEPTORS FOR ACTIVATED C KINASE; LEISHMANIA VACCINE; LEISHMANOLYSIN; METHIONINE AMINOPEPTIDASE 45; NUCLEOSIDASE; ORFF PROTEIN; PARASITE SURFACE ANTIGEN 2; PROTEIN DISULFIDE ISOMERASE; Q PROTEIN; THIOL SPECIFIC ANTIOXIDANT; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; ANTIGEN PRESENTING CELL; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; DISEASE CARRIER; DRUG EFFICACY; HUMAN; IMMUNIZATION; IMMUNOTHERAPY; LEISHMANIASIS; NONHUMAN; PRIORITY JOURNAL; REVIEW; SKIN LEISHMANIASIS; VISCERAL LEISHMANIASIS;

ANIMALS; ANTIGENS, PROTOZOAN; BIOMEDICAL RESEARCH; CLINICAL TRIALS AS TOPIC; HUMANS; LEISHMANIASIS; LEISHMANIASIS VACCINES; VACCINES, ATTENUATED; VACCINES, INACTIVATED; VACCINES, SUBUNIT;

EID: 84876741039     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.11.080     Document Type: Review

References (65)

1. WHO Technical Report Series. Control of the leshmaniasis 2010;949:1-201.
2. Croft S.L., Sundar S., Fairlamb A.H. Drug resistance in leishmaniasis. Microbiol Rev 2000, 19(1):111-126.
3. Handman E. Leishmaniasis: current status of vaccine development. Clin Microbiol Rev 2001, 14(2):229-243.
4. Palatnik-de-Sousa C.B. Vaccines for leishmaniasis in the fore coming 25 years. Vaccine 2008, 26(14):1709-1724.
5. Khamesipour A., et al. Leishmanization: use of an old method for evaluation of candidate vaccines against leishmaniasis. Vaccine 2005, 28:3642-3648.
6. Noazin S., et al. First generation leishmaniasis vaccines: a review of field efficacy trials. Vaccine 2008, 26(52):6759-6767.
7. Modabber F. Vaccine against leishmania. New generation vaccines 2009, 1040. Informa Healthcare, New York. 4th ed. M. Levine (Ed.).
8. Armijos R.X., et al. Field trial of a vaccine against New World cutaneous leishmaniasis in an at-risk child population: safety, immunogenicity, and efficacy during the first 12 months of follow-up. J Infect Dis 1998, 177(5):1352-1357.
9. Sharifi I., et al. Randomised vaccine trial of single dose of killed Leishmania major plus BCG against anthroponotic cutaneous leishmaniasis in Bam, Iran. Lancet 1998, 351(9115):1540-1543.
10. Khalil E.A., et al. Autoclaved Leishmania major vaccine for prevention of visceral leishmaniasis: a randomised, double-blind, BCG-controlled trial in Sudan. Lancet 2000, 356(9241):1565-1569.
11. Selvapandiyan A., et al. Intracellular replication-deficient Leishmania donovani induces long lasting protective immunity against visceral leishmaniasis. J Immunol 2009, 183(3):1813-1820.
12. Titus R.G., et al. Development of a safe live Leishmania vaccine line by gene replacement. Microbiology 1995, 92:10267-10271.
13. Uzonna J.E., et al. Vaccination with phosphoglycan-deficient Leishmania major protects highly susceptible mice fromvirulent challenge without inducing strong Th1 response. J Immunol 2004, 172:3793-3797.
14. Coler R.N., Reed S.G. Second-generation vaccines against leishmaniasis. Trends Parasitol 2005, 21(5):244-249.
15. Reed S.G., Scott P. T cell and cytokine responses in leishmaniasis. Curr Opin Immunol 1993, 5:524-531.
16. Kenney R.T., et al. Protective immunity using recombinant human IL-12 and alum as adjuvants in a primate model of cutaneous leishmaniasis. J Immunol 1999, 163(8):4481-4488.
17. Darrah P.A., et al. Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major. Nat Med 2007, 13(7):843-850.
18. Barral-Netto M., et al. Tranforming growth factor γ in leishmanial infection: an important parasite escapes mechanism. Science 1992, 257:545-548.
19. Ghalib H.G., Piuvezam M.R., Skeiky Y.A.W., Siddig M., Hashim F.A., El-Hassan A.M., Russo D.M., Reed S.G. Interleukin-10 production correlates with pathology in human Leishmania donovani infections. J Clin Invest 1993, 92:324-329.
20. Karp C.L., et al. The vivo cytokine profiles in patitents with kala-azar, marked elevation of both interleuking-10 and interferon-gamma. J Clin Invest 1993, 91(4):1644-1648.
21. Stobie L., et al. The role of antigen and IL-12 in sustaining Th1 memory cells in vivo: IL-12 is required to maintain memory/effector Th1 cells sufficient to mediate protection to an infectious parasite challenge. Proc Natl Acad Sci U S A 2000, 97(15):8427-8432.
22. Reed S.G., et al. Development of a leishmaniasis vaccine: the importance of MPL. Expert Rev Vaccines 2003, 2(2):239-252.
23. Belkaid Y., et al. Development of a natural model of cutaneous leishmaniasis: powerful effects of vector saliva and saliva preexposure on the long-term outcome of Leishmania major infection in the mouse ear dermis. J Exp Med 1998, 188(10):1941-1953.
24. Titus R.G. Salivary gland lysate from the sand fly Lutzomyia longipalpis supresses the immune response of mice to sheep red blood cells in vivo and concanavalin A in vitro. Exp Parasitol 1998, 89(1):133-136.
25. Kamhawi S., et al. Protection against cutaneous leishmaniasis resulting from bites of uninfected sand flies. Science 2000, 290(5495):1351-1354.
26. Morris R.V., et al. Sandfly maxadilan exacerbates infection with Leishmania major and vaccinating against it protects against L. major infection. J Immunol 2001, 167(9):5226-5230.
27. Kamhawi S., et al. A role for insect galectins in parasite survival. Cell 2004, 119(3):329-341.
28. de Moura T.R., et al. Enhanced Leishmania braziliensis infection following pre-exposure to sandfly saliva. PLoS Negl Trop Dis 2007, 1(2):e84.
29. Valenzuela J.G., et al. Toward a defined anti-Leishmania vaccine targeting vector antigens: characterization of a protective salivary protein. J Exp Med 2001, 194(3):331-342.
30. Gomes R., et al. Immunity to a salivary protein of a sand fly vector protects against the fatal outcome of visceral leishmaniasis in a hamster model. Proc Natl Acad Sci U S A 2008, 105(22):7845-7850.
31. Coutinho-Abreu I.V., et al. Targeting the midgut secreted PpChit1 reduces Leishmania major development in its natural vector, the sand fly Phlebotomus papatasi. PLoS Negl Trop Dis 2010, 4(11):901.
32. Walker P.S., et al. Immunostimulatory oligodeoxynucleotides promote protective immunity and provide systemic therapy for leishmaniasis via IL-12- and IFN-γ-dependent mechanisms. Proc Natl Acad Sci U S A 1999, 96(12):6970-6975.
33. Stacey K.J., Blackwell J.M. Immunostimulatory DNA as an adjuvant in vaccination against Leishmania major. Infect Immun 1999, 67(8):3719-3726.
34. Rhee E.G., et al. Vaccination with heat-killed leishmania antigen or recombinant leishmanial protein and CpG oligodeoxynucleotides induces long-term memory CD4+ and CD8+ T cell responses and protection against Leishmania major infection. J Exp Med 2002, 195(12):1565-1573.
35. Duthie M.S., et al. Use of defined TLR ligands as adjuvants within human vaccines. Immunol Rev 2011, 239(1):178-196.
36. Zhang W.W., Matlashewski G. Immunization with a Toll-like receptor 7 and/or 8 agonist vaccine adjuvant increases protective immunity against Leishmania major in BALB/c mice. Infect Immun 2008, 76(8):3777-3783.
37. Skeiky Y.A., et al. Protective efficacy of a tandemly linked, multi-subunit recombinant leishmanial vaccine (Leish-111f) formulated in MPL adjuvant. Vaccine 2002, 20(27-28):3292-3303.
38. Coler R.N., et al. Leish-111f, a recombinant polyprotein vaccine that protects against visceral leishmaniasis by elicitation of CD4+ T cells. Infect Immun 2007, 75(9):4648-4654.
39. Velez I.D., et al. Safety and immunogenicity of a defined vaccine for the prevention of cutaneous leishmaniasis. Vaccine 2009, 28(2):329-337.
40. Llanos-Cuentas A., et al. A clinical trial to evaluate the safety and immunogenicity of the LEISH-F1+MPL-SE vaccine when used in combination with sodium stibogluconate for the treatment of mucosal leishmaniasis. Vaccine 2010, 28(46):7427-7435.
41. Nascimento E., et al. A clinical trial to evaluate the safety and immunogenicity of the LEISH-F1+MPL-SE vaccine when used in combination with meglumine antimoniate for the treatment of cutaneous leishmaniasis. Vaccine 2010, 28(40):6581-6587.
42. Chakravarty J., et al. A clinical trial to evalutate the safety of immunogenicity of the LEISH-F1+MPL-SE vaccine for use in the prevention of visceral leishmaniasis. Vaccine 2011, 29(19):3531-3537.
43. Borja-Cabrera G.P., et al. Long lasting protection against canine kala-azar using the FML-QuilA saponin vaccine in an endemic area of Brazil (Sao Goncalo do Amarante RN). Vaccine 2002, 20(27-28):3277-3284.
44. Borja-Cabrera G.P., et al. Effective immunotherapy against canine visceral leishmaniasis with the FML-vaccine. Vaccine 2004, 22(17-18):2234-2243.
45. Saraiva E.M., et al. The FML-vaccine (Leishmune) against canine visceral leishmaniasis: a transmission blocking vaccine. Vaccine 2006, 24(13):2423-2431.
46. Trigo J., et al. Treatment of canine visceral leishmaniasis by the vaccine Leish-111f+MPL-SE. Vaccine 2010, 28(19):3333-3340.
47. Mougneau E., et al. Expression cloning of a protective Leishmania antigen. Science 1995, 268(5210):5630566.
48. Gomes D., et al. Intranasal delivery of naked DNA encoding the LACK antigen leads to protective immunity against visceral leishmaniasis in mice. Vaccine 2007, 25(12):2168-2172.
49. Ramiro N., et al. Protection in dogs against visceral leishmaniasis caused by Leishmania infantum is achieved by immunization with a heterologous prime-boost regime using DNA and vaccinia recombinant vectors expressing LACK. Vaccine 2003, 2003(19-20):2474-2484.
50. Russell D.G., Alexander J. Effective immunization against cutaneous leishmaniasis with defined membrane antigens reconstituted into liposomes. J Immunol 1988, 140(4):1274-1279.
51. Webb J.R., et al. Human and murine immune responses to a novel Leishmania major recombinant protein encoded by members of a multicopy gene family. Infect Immun 1998, 66(7):3279-3289.
52. Campos-Neto A., et al. Vaccination with plasmid DNA encoding TSA/LmSTI1 leishmanial fusion proteins confers protection against Leishmania major infection in susceptible BALB/c mice. Infect Immun 2002, 70(6):2828-2836.
53. Skeiky Y.A., et al. A recombinant Leishmania antigent that stimulates human peripheral blood mononuclear cells to express a Th1-type cytokine profile and to produce interleukin 12. J Exp Med 1995, 181(4):1527-1537.
54. Skeiky Y.A., et al. LeIF: a recombinant Leishmania protein that induces an IL-12-mediated Th1 cytokine profile. J Immunol 1998, 161(11):6171-6179.
55. Stager S., et al. Immunization with a recombinant stage-regulated surface protein from Leishmania donovani induces protection against viceral leishmaniasis. J Immunol 2000, 165(12):7064-7071.
56. Goto Y., et al. Protective immunization against visceral leishmaniasis using Leishmania sterol 24-c-methyltransferase formulated in adjuvant. Vaccine 2007, 25(42):7450-7458.
57. Basu R., et al. Kinetoplastid membrane protein-11 DNA vaccination induces complete protection against both pentavalent antimonial-sensitive and -resistant strains of Leishmania donovani that correlates with inducible nitric oxide synthase activity and IL-4 generation: evidence for mixed Th1- and Th2-like responses in visceral leishmaniasis. J Immunol 2005, 174(11):7160-7171.
58. Ghosh A., et al. Immunization with A2 protein results in a mixed Th1/Th2 and a humoral response which protects mice against Leishmania donovani infections. Vaccine 2001, 20(1-2):59-66.
59. Rafati S., et al. Prime-boost vaccination using cysteine proteinases type I and II of Leishmania infantum confers protective immunity in murine visceral leishmaniasis. Vaccine 2006, 24(12):2169-2175.
60. Goto Y., et al. KSAC, the first defined polyprotein vaccine candidate for visceral leishmaniasis. Clin Vaccine Immunol 2011, 18(7):1118-1124.
61. Aguilar-Be I., et al. Cross-protective efficacy of a prophylactic Leishmania donovani DNA vaccine against visceral and cutaneous murine leishmaniasis. Infect Immun 2005, 73(2):812-819.
62. Probst P.E., et al. Identification and characterization of T cell stimulating antigens from Leishmania by CD4 T cell expression cloning. J Immunol 2001, 166:498-505.
63. Gupta R., et al. A novel recombinant Leishmania donovani p45, a partial coding region of methionine aminopeptidase, generates protective immunity by inducing a Th1 stimulatory response against experimental visceral leishmaniasis. Int J Parasitol 2012, 42(5):429-435.
64. Kushawaha P., et al. Evaluation of Leishmania donovani protein disulfide isomerase as a potential immunogenic protein/vaccine candidate against visceral leishmaniasis. PLoS ONE 2012, 7(4):35670.
65. Kushawaha P., et al. Elongation factor-2, a Th1 stimulatory protein of Leishmania donovani, generates a strong IFNg and IL-12 response in cured Leishmania-infected patients/hamsters and protects hamsters against Leishmania challenge. J Immunol 2011, 187(12):6417-6427.